STERIS 2027 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- STERIS plc’s 2nd quarter 2027 as-reported revenue grew 9% to $1.6 billion, while constant currency organic revenue grew 8%, including 230 basis points of price.
- Adjusted gross margin was 45.3%, up 100 basis points year over year, and adjusted EBIT margin was 24.6%, up 150 basis points; tariff refunds of approximately $20 million contributed 130 basis points to each increase.
- Gross tariff costs were approximately $15 million in the 2nd quarter, flat with the prior year, while underlying gross margins were down slightly as favorable price was more than offset by inflation.
- Adjusted net income was $286.8 million, compared with $244.5 million in the prior year, and adjusted earnings per diluted share were $2.94, up 19% from $2.47; excluding tariff refunds, adjusted earnings per diluted share grew 13%.
- Free cash flow for the first 6 months was $492.5 million, compared with $527.7 million in the prior year period, and cash flow from operations was $656.1 million, compared with $707.8 million.
- STERIS ended the quarter with $1.9 billion in total debt and gross debt to EBITDA of approximately 1.1 times; 2nd quarter share buybacks totaled $100 million, or $200 million year-to-date, with $800 million remaining under the current authorization.
- Healthcare constant currency organic revenue grew 7%; service and consumables each grew 10%, capital equipment revenue increased 4%, orders grew 1%, and ending backlog increased to $456 million.
- Healthcare EBIT margin decreased 110 basis points to 24%, as improvements in volume and price were more than offset by inflation, lower productivity, and accelerated longer-term investments.
- AST constant currency organic revenue grew 5%, with services up 5% as reported or 6% constant currency; AST EBIT margin was 44.7%, down approximately 60 basis points year over year.
- Life Sciences constant currency organic revenue grew 18%, including capital equipment growth of 53%, consumables growth of 9%, and service revenue growth of 5%; backlog was $93 million, and margins reached a record 44.4%, up approximately 310 basis points.
- STERIS approved a restructuring plan with anticipated total charges of $45 million, including $10 million in cash expenditures and $35 million in non-cash charges; approximately $25 million was recorded in the 2nd quarter, and the plan is expected to generate annualized savings of approximately $9 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to the STERIS PLC Second Quarter 2027 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touchtone phone. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Julie Winter, Investor Relations.
Please go ahead. Thank you, Nick, and good morning, everyone.
Speaking on today's call will be Karen Burton, our Senior Vice President and CFO, and Dan Carestio, our President and CEO. I do have a few words of caution before we open for comments from management. This webcast contains time-sensitive information that is accurate only as of today. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. Some of the statements made during this review are or may be considered forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in STERIS' securities filings. Company does not undertake to update or revise any forward-looking statements as a result of new information or future events or developments. STERIS' SEC filings are available through the company and on our website.
In addition, on today's call, non-GAAP financial measures, including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and free cash flow will be used. Additional information regarding these measures, including definitions, is available in our release, as well as reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency to supplemental financial information used by management and the board of directors in their financial analysis and operational decision-making. With those cautions, I will hand the call over to Karen.
Thank you, Julie, and good morning, everyone. It is my pleasure to be with you this morning to review the highlights of our second quarter performance. For the second quarter, total as-reported revenue grew 9% to $1.6 billion. Constant currency organic revenue grew 8% in the quarter, driven by volume as well as 230 basis points of price. Adjusted gross margin for the quarter was 45.3%, up 100 basis points versus the prior year. Margin expansion was driven primarily by tariff refunds of approximately $20 million during the quarter, which added 130 basis points year-over-year. Underlying margins were down slightly as favorable price was more than offset by inflation. Gross tariff costs were approximately $15 million in the second quarter, flat with the prior year. For clarity, tariff refunds are not being allocated to our business segments, but instead are booked to corporate to enable business segment analysis.
Adjusted EBIT margin was 24.6% for the quarter, up 150 basis points from the second quarter last year. Tariff refunds contributed 130 basis points to the increase. Underlying margin improvement benefited from favorable price and volume, partially offset by inflation and investments in the business, including the acceleration of R&D spending. We do not expect any material additional tariff refunds during the remainder of fiscal 2027. The adjusted effective tax rate in the quarter was 25.3%, an increase from 24.5% in the second quarter of last year. The increase was primarily driven by unfavorable discrete items. Adjusted net income in the quarter was $286.8 million, compared with $244.5 million in the prior year. Adjusted earnings per share were $2.94, a 19% increase over $2.47 in the second quarter of last year. Excluding tariff refunds, adjusted earnings per diluted share grew 13%.
Capital expenditures for the second quarter were $76.1 million, and depreciation and amortization totaled $125.6 million. We ended the quarter with a strong balance sheet, reflecting $1.9 billion in total debt. Gross debt to EBITDA at quarter end was approximately 1.1 times. Free cash flow for the first six months was $492.5 million, compared with $527.7 million in the prior year period. Cash flow from operations was $656.1 million, compared with $707.8 million last year. The decline in cash flow was driven primarily by significantly lower contribution from working capital, as we utilized cash to build inventory in support of second-half shipments, partially offset by higher net income. Share buybacks in the second quarter totaled $100 million, or $200 million for the year to date. We have $800 million remaining under our current authorization.
During the quarter, we approved an additional restructuring plan covering targeted facility realignment product rationalization, and select organizational realignment. We anticipate total charges of $45 million, including $10 million in cash expenditures and $35 million in non-cash charges. Approximately $25 million was recorded in the second quarter. The plan is expected to generate annualized savings of approximately $9 million, with a portion realized in fiscal 2028 and the full benefit in subsequent fiscal years. With that, I will now turn the call over to Dan for his remarks.
Thanks, Karen, and good morning, everyone. Thank you for joining us to hear more about our second quarter 2027 performance and our outlook for the remainder of the year. Karen covered the quarter at a high level, so I will add some commentary on our segments. Starting with Healthcare, constant currency organic revenue grew 7% in the quarter. Our performance reflected solid underlying demand with continued strength in our GI business. The strength of our portfolio and commercial teams enables us to help our customers navigate a complex operating environment. Service continued its streak of outperformance, growing 10% in the second quarter. Consumables grew 10%, benefiting from increased customer consumption and driven by share gains, procedural growth in endoscopy, and to a lesser extent, a recent acquisition of GI products. Healthcare capital equipment revenue increased 4% in the quarter, also benefiting from a recent acquisition.
Orders remained stable with 1% growth in the second quarter, and our ending backlog increased to $456 million. EBIT margins for healthcare in the quarter decreased 110 basis points to 24%. Improvements in volume and price were more than offset by inflation, lower productivity, and longer-term investments we have accelerated on the back of tariff refunds. Turning to AST, constant currency organic revenue grew 5% for the quarter, with 5% growth in services as reported, or 6% constant currency. We ended the quarter on solid ground, and early indications suggest that October is holding those gains. EBIT margins for AST were 44.7%, a decrease of approximately 60 basis points from the second quarter of last year. The decline reflected increased depreciation and inflation, somewhat offset by improved pricing. Constant currency organic revenue increased 18% for life sciences for the quarter.
Supporting that growth, capital equipment grew 53%, and consumables increased 9%. Service revenue grew 5%. Reflecting strong shipments, backlog was $93 million at quarter end, down a bit from prior year. Margins were a record 44.4%, an increase of approximately 310 basis points, reflecting improvement in volume, price, productivity, and favorable mix. Reshoring and localization of manufacturing are benefiting our life sciences segment. Before we turn to the outlook, I do want to discuss our recently announced agreement to acquire Xodus Medical, a surgical specialties products business focused on patient and OR staff safety. Xodus Medical is a natural complement to our healthcare portfolio, expanding our consumables offering and the way we support customers in the operating room. The business is well-known for its flagship Pink Pad, a single-use surgical patient positioning product, but its portfolio is much broader.
Their products span patient positioning, patient handling and transfer, patient warming, and operating room essentials. This highly clinical, single-use portfolio will strengthen our recurring revenue and expand our direct commercial presence in the OR. Xodus has consistently demonstrated impressive growth, driven by a steady stream of innovation and highly effective commercial model. Our go-forward model reflects maintaining revenue growth in the mid-teens and EBIT margins in the low to mid-50s. The competitive clinical position is well-defined and supported by clinical studies, AORN guidelines, and a solid innovation pipeline, as well as intellectual property protection for core products. We are very excited about the opportunities ahead as our companies align to better serve customers. Shifting gears to outlook. Based on our second quarter results and our expectations for the remainder of the year, we are updating our outlook for fiscal 2027.
Our total company revenue growth expectations remain unchanged, including as-reported revenue growth of 7%-8% and constant currency organic growth of 6%-7%. Our fiscal 2027 earnings per diluted share outlook has been increased to $11.35-$11.55, compared with our prior range of $11.10-$11.30. This includes approximately $0.18 per share benefit from tariff refunds year-to-date in fiscal 2027. The additional increase in outlook was driven by second quarter outperformance and lower interest. From a segment perspective, we continue to expect healthcare constant currency organic revenue growth of 6%-7%. We now expect AST growth of 6%-7%, previously compared to the 7%-8%. This revision reflects us maintaining our exit rate from the second quarter for the balance of the year.
Based on the strong first half, we are increasing Life Sciences constant currency organic growth outlook to 9%-10%, compared with 6%-7% previously. This reflects a return to more normalized growth in the second half of the year, and the outperformance in the first half led by capital equipment. All other elements of our most recently provided outlook remain unchanged, but as a reminder, this outlook does not include Xodus Medical, and we will update our expectations after close. This is a very exciting time at STERIS. The business continues to perform very well, and we are able to prioritize investments in the business that will support our growth for years to come. I want to thank all of our associates for continuing to do what they do best, focus on our customers, and strive to do a little better each day.
That concludes our prepared remarks for the call. Nick, would you please give the instructions, and we can begin the Q&A.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
